市場調査レポート

商品コード

1403426

遅発性ジスキネジア治療薬の2030年までの世界市場予測：製品タイプ、疾患タイプ、投与経路、流通チャネル、地域別分析

Tardive Dyskinesia Therapeutics Market Forecasts to 2030 - Global Analysis By Product Type, Disease Type, Route Of Administration, Distribution Channel and By Geography

出版日: 2024年01月01日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 652,131円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 824,985円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 997,839円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,178,550円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、遅発性ジスキネジア治療薬の世界市場は2023年に25億米ドルを占め、予測期間中のCAGRは11.1％で成長し、2030年には54億米ドルに達する見込みです。

遅発性ジスキネジア（TD）と呼ばれる薬物誘発性の運動状態は、舌、顔、胴体、手足を制御不能に動かしてしまいます。遅発性ジスキネジアは、抗精神病薬など特定の精神科治療薬の長期使用によって起こる副作用です。時には他の患者を苦しめることもあるが、この病気は精神分裂病、統合失調感情障害、双極性障害で抗精神病薬を長期服用した患者に最も多く見られます。

John Wiley &Sons, Inc.が2022年8月に発表した論文によると、欧州における遅発性ジスキネジアの有病率は、抗精神病薬による治療を受けている精神科患者の23.3%です。

遅発性ジスキネジアの有病率の上昇

意識の高まりは、早期の発見と対処を促し、症状の重篤度を軽減する可能性があります。研究の進歩により、より専門的な薬剤や治療法が開発され、影響を受けた人々により個別的なケアが提供されるようになります。さらに、認知度の向上は、さらなる研究のための資金調達を促し、創造性を刺激し、遅発性ジスキネジアの治療や予防に対する新たなアプローチを明らかにし、最終的にはこの疾患に罹患している人々の生活の質を向上させる。

複雑な管理

遅発性ジスキネジアの管理は、現在の処方を変更したり、新たな処方を追加したりするなど、様々な戦略を組み合わせて行われることが多いです。このような複雑さは、特に元の薬が処方された基礎疾患を管理する必要性と両立させる場合、治療を困難にすることがあります。管理するための治療法には、軽度なものから重度なものまで様々な副作用があり、綿密なモニタリングと管理が必要となる場合があります。

認識と診断の向上

早期発見によりタイムリーな管理が可能となり、経過を遅らせ、患者の転帰を改善することができます。知識が深まることで、ヘルスケア専門家が積極的に患者をモニタリングするようになり、処方スケジュールの迅速な変更や他の治療法の使用による症状のコントロールが容易になります。さらに、知識が深まることで、患者の教育やサポートが促進され、スティグマが軽減され、ヘルスケアへの思いやりのあるアプローチが促されます。このような包括的な戦略は、最終的には人々のQOLを向上させ、市場の拡大を促進します。

製薬会社による研究開発投資の制限

希少疾患治療薬の研究開発における大きな課題のひとつは、臨床試験に参加できる患者数が少ないことです。臨床試験に参加できる希少疾患患者は数百人か数千人に過ぎないです。希少疾患の患者数はごくわずかなのです。さらに、調査には費用がかかり、投資に対する見返りも曖昧であるため、製薬企業は資金提供に消極的になる可能性があります。

COVID-19影響：

パンデミックは世界のヘルスケアサービスの混乱を引き起こし、定期検診、専門医へのアクセス、対面治療の利用可能性などに影響を与えました。そのため、多くの遅発性ジスキネジア患者の治療が遅れたり中断したりしました。COVID-19は遅発性ジスキネジアに関連する進行中の臨床試験や調査研究の進捗に影響を与えました。一部の臨床試験は、面会制限や登録の課題により、遅延または変更された可能性があります。

予測期間中、deutetrabenazineセグメントが最大となる見込み

予測期間中、重テトラベナジンセグメントが最大となる見込みです。重水素置換により半減期が延長されるため、有効性と安全性のプロファイルが向上し、投与に関連する副作用が減少し、患者のアドヒアランスが改善されます。この化合物は、遅発性ジスキネジアに関連する不随意運動を抑制し、より一貫性のある管理しやすい治療アプローチを提供する可能性を示しています。

遅発性ジストニア領域は予測期間中に最も高いCAGRが見込まれる

遅発性ジストニア分野は、予測期間中に最も高いCAGRが見込まれます。遅発性ジストニアは、遅発性ジスキネジアのサブタイプであり、具体的には、反復的なねじれ運動や異常な姿勢を引き起こす持続的な筋収縮を伴う。遅発性ジストニアの引き金となる薬剤を調整または中止することで、症状が改善または消失することもあります。しかし、この場合は、医療専門家によって慎重に管理され、薬物の有益性と精神状態を悪化させるリスクとのバランスをとる必要があります。

最大のシェアを占める地域

予測期間中、北米が最大の市場シェアを占めると予測されています。複数の製薬会社が、症状の管理に特化した薬剤の開発に投資しています。これらの治療薬は、疾患に伴う不随意運動を緩和することで、罹患者の生活の質を向上させることを目的としています。同市場は、治療法の選択肢の進歩やヘルスケアプロバイダーの間でこれらの治療法が受け入れられつつあるという点で成長を示しています。

CAGRが最も高い地域：

アジア太平洋地域は、ヘルスケア意識の高まり、診断技術の向上、高齢化により、予測期間中最も高いCAGRを維持すると予測されます。製薬会社は、この分野におけるアンメット・メディカル・ニーズへの対応を目指し、症状をターゲットとした新しい治療法や薬の開発に取り組んでいます。国内製薬企業と世界製薬企業との提携や、診断・治療技術の進歩も、同地域の市場拡大に寄与しています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Mitsubishi Tanabe Pharma Corporation
Luye Pharma Group
Teva Pharmaceutical Industries Ltd.
Neurocrine Biosciences, Inc.
SOM BIOTECH
Sun Pharmaceutical Industries Ltd
AbbVie Inc
Sanis
SteriMax Inc.
Adamas Pharmaceuticals, Inc
Reddys Laboratories Ltd
Mylan N.V.
Bausch Health
Johnson & Johnson Services
Lupin Pharmaceuticals Inc
Novartis AG
Baxter
Amgen Inc
Pfizer Inc
Medicure Inc

図表

List of Tables

Table 1 Global Tardive Dyskinesia Therapeutics Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
Table 3 Global Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
Table 4 Global Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
Table 5 Global Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
Table 6 Global Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
Table 7 Global Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 8 Global Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
Table 9 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
Table 10 Global Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
Table 11 Global Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
Table 12 Global Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
Table 13 Global Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
Table 14 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
Table 15 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
Table 16 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
Table 17 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
Table 18 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
Table 19 Global Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
Table 20 Global Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
Table 21 Global Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
Table 22 Global Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 23 Global Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 24 Global Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
Table 25 Global Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 26 Global Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 27 North America Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 28 North America Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
Table 29 North America Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
Table 30 North America Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
Table 31 North America Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
Table 32 North America Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
Table 33 North America Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 34 North America Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
Table 35 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
Table 36 North America Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
Table 37 North America Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
Table 38 North America Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
Table 39 North America Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
Table 40 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
Table 41 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
Table 42 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
Table 43 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
Table 44 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
Table 45 North America Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
Table 46 North America Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
Table 47 North America Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
Table 48 North America Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 49 North America Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 50 North America Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
Table 51 North America Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 52 North America Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 53 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 54 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
Table 55 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
Table 56 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
Table 57 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
Table 58 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
Table 59 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 60 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
Table 61 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
Table 62 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
Table 63 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
Table 64 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
Table 65 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
Table 66 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
Table 67 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
Table 68 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
Table 69 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
Table 70 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
Table 71 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
Table 72 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
Table 73 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
Table 74 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 75 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 76 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
Table 77 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 78 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 79 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 80 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
Table 81 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
Table 82 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
Table 83 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
Table 84 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
Table 85 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 86 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
Table 87 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
Table 88 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
Table 89 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
Table 90 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
Table 91 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
Table 92 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
Table 93 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
Table 94 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
Table 95 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
Table 96 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
Table 97 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
Table 98 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
Table 99 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
Table 100 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 101 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 102 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
Table 103 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 104 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 105 South America Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 106 South America Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
Table 107 South America Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
Table 108 South America Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
Table 109 South America Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
Table 110 South America Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
Table 111 South America Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 112 South America Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
Table 113 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
Table 114 South America Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
Table 115 South America Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
Table 116 South America Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
Table 117 South America Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
Table 118 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
Table 119 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
Table 120 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
Table 121 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
Table 122 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
Table 123 South America Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
Table 124 South America Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
Table 125 South America Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
Table 126 South America Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 127 South America Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 128 South America Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
Table 129 South America Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 130 South America Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 131 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 132 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
Table 133 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
Table 134 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
Table 135 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
Table 136 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
Table 137 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 138 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
Table 139 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
Table 140 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
Table 141 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
Table 142 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
Table 143 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
Table 144 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
Table 145 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
Table 146 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
Table 147 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
Table 148 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
Table 149 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
Table 150 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
Table 151 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
Table 152 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 153 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 154 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
Table 155 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 156 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Product Code: SMRC24651

According to Stratistics MRC, the Global Tardive Dyskinesia Therapeutics Market is accounted for $2.5 billion in 2023 and is expected to reach $5.4 billion by 2030 growing at a CAGR of 11.1% during the forecast period. A drug-induced movement condition called tardive dyskinesia (TD) results in uncontrollably moving the tongue, face, torso, and limbs. It is a side effect brought on by extended use of specific psychiatric drug classes, such antipsychotics. Although they sometimes afflict other patients as well, the illness is most frequent among those who have been taken long-term antipsychotic drugs for schizophrenia, schizoaffective disorder, or bipolar disorder.

According to an article published by John Wiley & Sons, Inc., in August 2022, the prevalence of tardive dyskinesia in Europe is 23.3% amongst psychiatric patients receiving treatment with antipsychotics.

Market Dynamics:

Driver:

Rising prevalence of tardive dyskinesia

Increased consciousness encourages early identification and action, which may lessen the severity of symptoms. Research progresses lead to the creation of more specialized drugs and therapies, providing impacted people with more individualized care. Furthermore, greater awareness encourages financing for additional research, which spurs creativity and reveals fresh approaches to tardive dyskinesia therapy and prevention, eventually enhancing the quality of life for individuals affected by the disorder.

Restraint:

Complexity in management

The management of tardive dyskinesia frequently entails a mix of strategies, such as changing current prescriptions or adding new ones. This intricacy can make treatment difficult, particularly when juggling the requirement to manage the underlying condition for which the original medication was prescribed. Therapeutic options for management have a range of side effects, from mild to severe, which may require close monitoring and management.

Opportunity:

Increased awareness and diagnosis

Early detection enables timely management, which may slow its course and enhance patient outcomes. Increased knowledge encourages healthcare professionals to monitor patients proactively, which makes it easier to control symptoms by promptly changing prescription schedules or using other therapies. Moreover, better knowledge promotes patient education and support, lessens stigma, and encourages a more compassionate approach to healthcare. This all-encompassing strategy eventually improves people's quality of life, which fuels market expansion.

Threat:

Limited R&D investment by pharmaceutical companies

One of the major challenges of rare disease drugs in terms of research and development is the small patient population available for clinical trials. Only a few hundred or few thousand patients with rare diseases are accessible for clinical trials. Rare diseases afflict a tiny population. Furthermore, because research may be expensive and have hazy returns on investment, pharmaceutical corporations could be reluctant to fund it.

COVID-19 Impact:

The pandemic caused disruptions in healthcare services globally, affecting regular check-ups, access to specialists, and availability of in-person treatments. This led to delays or interruptions in treatment for many individuals with tardive dyskinesia. COVID-19 impacted the progress of ongoing clinical trials and research studies related to tardive dyskinesia. Some trials might have been delayed or modified due to restrictions on in-person visits and enrollment challenges.

The deutetrabenazine segment is expected to be the largest during the forecast period

The deutetrabenazine segment is expected to be the largest during the forecast period. Its deuterium substitution enhances its efficacy and safety profile by prolonging its half-life, leading to fewer dose-related side effects and improved patient adherence. This compound demonstrates potential in reducing involuntary movements associated with Tardive Dyskinesia while offering a more consistent and manageable treatment approach.

The tardive dystonia segment is expected to have the highest CAGR during the forecast period

The tardive dystonia segment is expected to have the highest CAGR during the forecast period. Tardive dystonia, a subtype of tardive dyskinesia, specifically involves sustained muscle contractions causing repetitive, twisting movements or abnormal postures. Sometimes, adjusting or discontinuing the medications that trigger tardive dystonia can lead to improvement or resolution of symptoms. However, this must be carefully managed by a healthcare professional to balance the benefits of the medication with the risk of worsening psychiatric conditions.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Several pharmaceutical companies have been investing in developing medications specifically targeted to manage symptoms. These treatments aim to alleviate the involuntary movements associated with the condition, thereby improving the quality of life for affected individuals. The market has shown growth in terms of advancements in therapeutic options and the growing acceptance of these treatments among healthcare providers.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to rising healthcare awareness, improving diagnostic techniques, and an aging population. Pharmaceutical companies were working on developing new treatments and medications targeting symptoms, aiming to address the unmet medical needs in this area. Collaborations between local and global pharmaceutical companies, as well as advancements in technology for diagnosis and treatment, were also contributing to the expansion of the market in the region.

Key players in the market:

Some of the key players in Tardive Dyskinesia Therapeutics market include Mitsubishi Tanabe Pharma Corporation, Luye Pharma Group, Teva Pharmaceutical Industries Ltd., Neurocrine Biosciences, Inc., SOM BIOTECH, Sun Pharmaceutical Industries Ltd, AbbVie Inc , Sanis, SteriMax Inc., Adamas Pharmaceuticals, Inc , Reddys Laboratories Ltd, Mylan N.V., Bausch Health, Johnson & Johnson Services, Lupin Pharmaceuticals Inc, Novartis AG, Baxter, Amgen Inc, Pfizer Inc and Medicure Inc.

Key Developments:

In February 2023, Teva Pharmaceuticals announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on different aspects of a patient's daily functioning.

In December 2021, Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical K.K. have entered into a co-promotion agreement for MT-5199, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, which is intended for use as tardive dyskinesia therapeutics in Japan.

Product Types Covered:

Valbenazine
Deutetrabenazine
Clonazepam
Vitamin E
Benzodiazepines
Ondansetron
Tetrabenazine
Reserpine
Propranolol
Dopamine-Depleting Agents

Disease Types Covered:

Tardive akathisia
Tardive Orofacial Dyskinesia
Tardive Dystonia
Tardive Blepharospasm
Tardive Tics

Route Of Administration Covered:

Oral
Injectable

Distribution Channels Covered:

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies
Other Distribution Channels

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Tardive Dyskinesia Therapeutics Market, By Product Type

5.1 Introduction
5.2 Valbenazine
5.3 Deutetrabenazine
5.4 Clonazepam
5.5 Vitamin E
5.6 Benzodiazepines
5.7 Ondansetron
5.8 Tetrabenazine
5.9 Reserpine
5.10 Propranolol
5.11 Dopamine-Depleting Agents

6 Global Tardive Dyskinesia Therapeutics Market, By Disease Type

6.1 Introduction
6.2 Tardive akathisia
6.3 Tardive Orofacial Dyskinesia
6.4 Tardive Dystonia
6.5 Tardive Blepharospasm
6.6 Tardive Tics

7 Global Tardive Dyskinesia Therapeutics Market, By Route Of Administration

7.1 Introduction
7.2 Oral
7.3 Injectable

8 Global Tardive Dyskinesia Therapeutics Market, By Distribution Channel

8.1 Introduction
8.2 Hospital Pharmacies
8.3 Drug Stores & Retail Pharmacies
8.4 Online Pharmacies
8.5 Other Distribution Channels

9 Global Tardive Dyskinesia Therapeutics Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Mitsubishi Tanabe Pharma Corporation
11.2 Luye Pharma Group
11.3 Teva Pharmaceutical Industries Ltd.
11.4 Neurocrine Biosciences, Inc.
11.5 SOM BIOTECH
11.6 Sun Pharmaceutical Industries Ltd
11.7 AbbVie Inc
11.8 Sanis
11.9 SteriMax Inc.
11.10 Adamas Pharmaceuticals, Inc
11.11 Reddys Laboratories Ltd
11.12 Mylan N.V.
11.13 Bausch Health
11.14 Johnson & Johnson Services
11.15 Lupin Pharmaceuticals Inc
11.16 Novartis AG
11.17 Baxter
11.18 Amgen Inc
11.19 Pfizer Inc
11.20 Medicure Inc

遅発性ジスキネジア治療薬の2030年までの世界市場予測：製品タイプ、疾患タイプ、投与経路、流通チャネル、地域別分析

Tardive Dyskinesia Therapeutics Market Forecasts to 2030 - Global Analysis By Product Type, Disease Type, Route Of Administration, Distribution Channel and By Geography

COVID-19影響：

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の遅発性ジスキネジア治療薬市場：製品タイプ別

第6章 世界の遅発性ジスキネジア治療薬市場：疾患タイプ別

第7章 世界の遅発性ジスキネジア治療薬市場：投与経路別

第8章 世界の遅発性ジスキネジア治療薬市場：流通チャネル別

第9章 世界の遅発性ジスキネジア治療薬市場：地域別

第10章 主な発展

第11章 企業プロファイル